MLYS Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Mineralys Therapeutics, Inc.

Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup

11 days ago - By: Zacks Investment Research

Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet

19 days ago - By: The Motley Fool - Mentions: LQDA ESTA OPRT ODP ...

This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys

20 days ago - By: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Benzinga

Uncovering Potential: Mineralys Therapeutics's Earnings Preview

a month ago - By: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

a month ago - By: Mineralys Therapeutics, Inc.

Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025

3 months ago - By: The Motley Fool - Mentions: NKTR

These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?

4 months ago - By: Benzinga

Earnings Preview For Mineralys Therapeutics

3 months ago - By: Zacks Investment Research

What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now?

3 months ago - By: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need

3 months ago - By: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

3 months ago - By: Yahoo Finance

Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak

3 months ago - By: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

3 months ago - By: Mineralys Therapeutics, Inc.

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

4 months ago - By: Investor's Business Daily - Mentions: GS AZN

AstraZeneca's $80 Billion Ambition Just Got A Big Infusion With New Hypertension Results

4 months ago - By: Zacks Investment Research

MINERALYS THERAPEUTICS INC (MLYS) Stock News

MLYS Latest News, Press Relases and Analysis

Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” Roundup

Wall Street Analysts Think Mineralys Therapeutics, Inc. (MLYS) Could Surge 27.55%: Read This Before Placing a Bet

This Fund Leaned Into 2025's Big Biotech Rally with a $9.5 Million Bet on Mineralys

Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Uncovering Potential: Mineralys Therapeutics's Earnings Preview

Mineralys Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Data for Lorundrostat in Chronic Kidney Disease and Hypertension Presented at American Society of Nephrology (ASN) Kidney Week 2025

These 2 Healthcare Stocks Are Up Over 100% in a Month. Can They Keep Climbing?

Earnings Preview For Mineralys Therapeutics

What Makes Mineralys Therapeutics, Inc. (MLYS) a Strong Momentum Stock: Buy Now?

Mineralys Therapeutics Presents Subgroup Analyses of Phase 3 Launch-HTN Trial Demonstrating Efficacy and Safety of Lorundrostat in Hypertension Participants with High Unmet Medical Need

Mineralys Therapeutics Announces Closing of Upsized $287.5 Million Underwritten Public Offering of Common Stock Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

Mineralys (MLYS) Steals Spotlight From AstraZeneca, Reaches Fresh Peak

Mineralys Therapeutics Announces Pricing of Upsized $250.0 Million Underwritten Public Offering of Common Stock

Mineralys Therapeutics Announces Proposed Public Offering of Common Stock

AstraZeneca's $80 Billion Ambition Just Got A Big Infusion With New Hypertension Results

Wall Street Analysts Believe Mineralys Therapeutics, Inc. (MLYS) Could Rally 149.66%: Here's is How to Trade